LATEST ALERTSSome sellers of intoxicating cannabinoid products claim legality under the 2018 US Farm Bill. CBD-Intel believes that many hemp-derived cannabinoids do not violate federal controlled substance law
The UK’s National Health Service (NHS) has expressed some interest in the viability of psychedelics as a course of treatment
CBD-Intel podcast editor Jon Bruford meets Dr K CBD’s Dr Ruchira Karunadasa who explains why he believes the company has an important role to play in helping the industry towards mature dialogue, and the impact that
Rahul Gupta has been confirmed by the US Senate as director of National Drug Control Policy, while president Joe Biden intends to nominate Robert Califf as head of the US Food and Drug Administration (FDA)
A research team at the University Medical Center Groningen (UMCG) in the Netherlands recently launched a three-year study into whether medicinal cannabis oil can help to regress liver-cancer tumours
Another study, this time from Italy, has found potentially dangerous levels of heavy metals and pesticides in CBD products. Researchers were worried by the results and asked regulators and legislators to act
Interest in the Brazilian medical cannabinoid market is based on optimistic projections of growth continuing in the same vein rather than concrete current numbers, a domestic report has confirmed
Interest in psychedelic drugs and treatments continues to grow, as evidenced by three major takeovers in Canada and the USA, two involving drug treatments developments and another offering a network of ketamine infusion treatment centres
It turns out the Charlotte’s Web application to the US FDA for the registration of a full spectrum hemp extract as a new dietary ingredient (NDI) DID include data from the ValidCare industry study
Two North American entrepreneurs have put millions of dollars into exploring the treatment efficacy of psychedelics, based on personal experience of using them to help deal with their own mental health issues
German imports of medical cannabis flowers rose by 80% in the first half of 2021 compared to the same period of 2021, but hopes of establishing local production were dashed
The US Drug Enforcement Agency (DEA) is calling for an increase in production of cannabis and psychedelics to supply federal research and clinical trials
NFL veteran Chris Hetherington has launched a CBD oil derived entirely from orange peel, describing it as “crystalline CBD at a purity and consistency difficult to match with cannabis or hemp-derived material”
CBD pet products remain in a grey area in terms of both legality and effectiveness – but there have been some attempts in both to shed light into the darkness
Two new studies on the biochemistry of cannabinoids could provide answers to a puzzling question – how does the entourage effect work?
A court case could force the Canadian government to process requests to use psilocybin for psychotherapeutic treatment more quickly
A recent ring trial assessment of the lab performances and methods for measuring CBD in commercial products has given some good news to the industry
A new study has shown some limited effectiveness for the use of CBD in combatting nicotine withdrawal symptoms
New methods for laboratory production of cannabinoids show some promise – but it’s still not clear whether they will yield enough to be commercially viable
Researchers at the University of San Diego in California have published a paper showing early evidence that CBD may help ease the symptoms of nicotine withdrawal
Public health insurance reimbursements and no defined list of indications for medical cannabis have helped the German medical cannabis market start to realise its massive potential
Research from a CBD watchdog firm has found considerable inconsistencies between the levels of delta-8 THC stated on product labels and what was revealed by laboratory tests
Both synthetic and plant-derived CBD degrade when stored incorrectly, producing THC, according to a new study
London-listed Kanabo has launched the first medical cannabis vaping product in the UK in a move the company’s founder hopes will ultimately revolutionise the way medicines are administered
Medical cannabis advocates are keen to see if Sajid Javid’s appointment as UK health secretary means he will continue his work from 2018, when he helped change the law on medicinal cannabis prescriptions
A range of European firms are looking to further advance research into psychedelic compounds after securing funding and backing
A year and eight months after Cibdol submitted its novel food application for EU authorisation of synthetically produced CBD, the Swiss company is still fielding questions from the European Food Safety Authority (ESFA)
What are the potential implications for the cannabinoids market of two recently discovered compounds with chemical structures similar to those of CBD and THC – and what are they and their potential effects anyway?
France is lagging behind its neighbours on medical cannabis – the potential “green pig” of French agriculture – according to an author of a report which called for it to be legalised on health and finance grounds
CBD-Intel podcast editor Jon Bruford discusses the situation of medical cannabis and the challenges of hemp-growing in the UK with Dr Callie Seaman, research director at Aqualabs Ltd
Trends such as sustainability and organic plant-based ingredients are helping to drive the market for hemp and cannabinoid topical products even higher, with combination products all the rage
CBD-Intel assesses how Project Twenty21 is faring as it seeks to construct a registry of medical cannabis users in the UK and Europe, providing real world data on potential efficacy
Pain is a familiar part of everybody’s life, yet it remains a remarkably hard subject to study. It therefore is unsurprising that studies have come to differing conclusions on the use of cannabis and cannabinoids for pain relief
CBD-Intel offers a review of the science behind some of cannabis’s lesser-known compounds – the so-called “minor cannabinoids” – with an emphasis on their potential applications
In comparison with our 2019 consumer survey results, the reasons given for using CBD have changed and diversified
Early research into the possibility of CBD having a role to play in the fight against coronavirus infections has shown some initial promise. Any practical application remains a long way off, however
Australian medicinal cannabis firm Cann has moved quickly to maximise the benefits of its CBD Gelpell capsule technology by entering into a collaboration deal with healthcare technology firm Emyria
While legal cannabis is still a relatively new industry, investors are already looking for the next sector to boom – and many think that will be psychedelics
Canadian cannabis firm Tilray is moving in on New Zealand’s market for medical cannabis and has received the necessary approvals to launch Tilray medical cannabis products across the country
Could cannabinoids, including CBD, provide a partial solution to the growing danger of diseases becoming resistant to existing antibiotics?
Scientific findings on the antimicrobial properties of cannabis – and in particular cannabinoids – have raised the question of whether they might play a role in combatting antibiotic-resistant bacteria such as MRSA
The CEO of one company targeted by the US Federal Trade Commission (FTC) in the first ever group of fines handed down by the government agency to CBD companies considers the event to be a David and Goliath victory of sorts
No evidence of liver toxicity from CBD has been found in the ValidCare study, the results of which have been given to the US Food and Drug Administration (FDA) for review
Any conclusion drawn from studies on rodents must be treated with caution if we want to know about effects on humans
The US Food and Drug Administration (FDA) has called for an exploration of the effects of CBD on certain vulnerable populations such as children and pregnant women as part of its consumer update
GW Pharmaceuticals, the British manufacturer of the CBD-based epilepsy drug Epidiolex, has been acquired by Jazz Pharmaceuticals in a cash and shares deal worth over $7bn
Renewed interest in financing of CBD and cannabis businesses could signal that investors are starting to be positive again about the future after companies seemingly weathered the worst of the storm in 2020
Dutch officials have granted a six-month reprieve to find a solution to an omission in the Brexit negotiations that threatens to deprive British epilepsy patients of access to cannabis-based medicines
Find all of CBD-Intel’s coronavirus-related regulatory alerts here, updated as they appear
For many 2020 will always carry an asterisk. The CBD industry was – overall – more fortunate than many other sectors
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.
"*" indicates required fields
Get 7 days of access to industry updates through our news analysis and regulatory alerts
"*" indicates required fields
